Evidence map›Paper›PMID 31752976›Full record

ArticleCritical care (London, England)2019

Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study.

Philippe Guerci, Hugo Bellut, Mokhtar Mokhtari, Julie Gaudefroy, Nicolas Mongardon, Claire Charpentier, Guillaume Louis, Parvine Tashk, Clément Dubost, Stanislas Ledochowski and 8 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Critical care (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03506191 (Pneumonia Due to Stenotrophomonas Maltophilia in Intensive Care Units), which is not on this map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03506191 unknown statusnot on this map

Pneumonia Due to Stenotrophomonas Maltophilia in Intensive Care Units: a Multicentre Retrospective Study

TypeobservationalSponsorGroupe Hospitalier Pitie-SalpetriereRan2017 to 2018Enrolled300ConditionsPneumonia, Ventilator-Associated, Stenotrophomonas Infection, Critical Illness, Pneumonia, Bacterial
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Observational
  12. Multicenter epidemiology ofFrontiers in microbiology · 2025
    Article
  13. Screening and comparison ofFrontiers in cellular and infection microbiology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Pathogens (Basel, Switzerland) · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 2 countries.

Philippe GuerciDepartment of Anaesthesiology and Critical Care Medicine, Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy-Brabois, Vandoeuvre-Lès-Nancy, France.
Hugo BellutSorbonne Université, Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Anaesthesiology and Critical Care Medicine, Institute of Cardiology, Pitié-Salpêtrière Hospital, 47-83 Boulevard de l'Hôpital, 75013, Paris, France.
Mokhtar MokhtariDepartment of Anaesthesiology and Critical Care Medicine, Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy-Brabois, Vandoeuvre-Lès-Nancy, France.
Julie GaudefroyService d'Anesthésie-Réanimation Chirurgicale, Hôpital Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Nicolas MongardonService d'Anesthésie-Réanimation, Hôpital Henri Mondor, DMU CARE, Assistance Publique - Hôpitaux de Paris (AP-HP), Inserm U955 équipe 3, Université Paris-Est Créteil, Créteil, France.
Claire CharpentierRéanimation Chirurgicale Polyvalente, Hôpital Central, Centre Hospitalier Universitaire de Nancy, Nancy, France.
Guillaume LouisRéanimation polyvalente, Hôpital de Mercy, CHR Metz-Thionville, Metz, France.
Parvine TashkService d'Anesthésie-Réanimation, Hôpital Bichat-Claude Bernard, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.
Clément DubostRéanimation polyvalente, Hôpital d'Instruction des Armées (HIA) Bégin, Saint-Mandé, France.
Stanislas LedochowskiService de Réanimation Polyvalente, Groupement Hospitalier Nord Dauphiné- Centre Hospitalier Pierre Oudot, Bourgoin-Jallieu, France.
Antoine KimmounRéanimation Médicale, Institut Lorrain du Cœur et des Vaisseaux, CHU Nancy-Brabois, Vandoeuvre-Lès-Nancy, France.
Thomas GodetRéanimation Adultes et Soins Continus, Pôle de Médecine Péri-opératoire, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.
Julien PottecherService d'Anesthésie-Réanimation Chirurgicale, Hôpital Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Jean-Marc LalotService d'Anesthésie-Réanimation, Réanimation polyvalente, Centre Hospitalier Emile Durkheim, Epinal, France.
Emmanuel NovyDepartment of Anaesthesiology and Critical Care Medicine, Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy-Brabois, Vandoeuvre-Lès-Nancy, France.
David HajageDépartement Biostatistique Santé Publique Et Information Médicale, Unité de Recherche Clinique PSL-CFX, Centre de Pharmacoépidémiologie (Cephepi), Sorbonne Université, INSERM, Institut Pierre Louis de Santé Publique, Equipe Pharmacoépidémiologie et évaluation des soins, AP-HP, Hôpital Pitié-Salpêtrière, CIC-1421, Paris, France.
Adrien BougléSorbonne Université, Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Anaesthesiology and Critical Care Medicine, Institute of Cardiology, Pitié-Salpêtrière Hospital, 47-83 Boulevard de l'Hôpital, 75013, Paris, France. adrien.bougle@aphp.fr.ORCID 0000-0002-8990-4705
AZUREA research network
Centre Hospitalier Régional et Universitaire de Nancy · FRInserm · FRHôpitaux Universitaires de Strasbourg · FRSorbonne Université · FRCentre Hospitalier De Pau · FRCentre hospitalier Emile Roux · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Nantes · FRHôpital d'Instruction des Armées Bégin · FRHôpital Femme Mère Enfant · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is little descriptive data on Stenotrophomonas maltophilia hospital-acquired pneumonia (HAP) in critically ill patients. The optimal modalities of antimicrobial therapy remain to be determined. Our objective was to describe the epidemiology and prognostic factors associated with S. maltophilia pneumonia, focusing on antimicrobial therapy.

methodsThis nationwide retrospective study included all patients admitted to 25 French mixed intensive care units between 2012 and 2017 with hospital-acquired S. maltophilia HAP during intensive care unit stay. Primary endpoint was time to in-hospital death. Secondary endpoints included microbiologic effectiveness and antimicrobial therapeutic modalities such as delay to appropriate antimicrobial treatment, mono versus combination therapy, and duration of antimicrobial therapy.

resultsOf the 282 patients included, 84% were intubated at S. maltophilia HAP diagnosis for duration of 11 [5-18] days. The Simplified Acute Physiology Score II was 47 [36-63], and the in-hospital mortality was 49.7%. Underlying chronic pulmonary comorbidities were present in 14.1% of cases. Empirical antimicrobial therapy was considered effective on S. maltophilia according to susceptibility patterns in only 30% of cases. Delay to appropriate antimicrobial treatment had, however, no significant impact on the primary endpoint. Survival analysis did not show any benefit from combination antimicrobial therapy (HR = 1.27, 95%CI [0.88; 1.83], p = 0.20) or prolonged antimicrobial therapy for more than 7 days (HR = 1.06, 95%CI [0.6; 1.86], p = 0.84). No differences were noted in in-hospital death irrespective of an appropriate and timely empiric antimicrobial therapy between mono- versus polymicrobial S. maltophilia HAP (p = 0.273). The duration of ventilation prior to S. maltophilia HAP diagnosis and ICU length of stay were shorter in patients with monomicrobial S. maltophilia HAP (p = 0.031 and p = 0.034 respectively).

conclusionsS. maltophilia HAP occurred in severe, long-stay intensive care patients who mainly required prolonged invasive ventilation. Empirical antimicrobial therapy was barely effective while antimicrobial treatment modalities had no significant impact on hospital survival.

trial registrationclinicaltrials.gov, NCT03506191.

Indexed as

AgedAnti-Infective AgentsFemaleFollow-Up StudiesGram-Negative Bacterial InfectionsHealthcare-Associated PneumoniaHospital MortalityHumansIntensive Care UnitsMaleMiddle AgedPneumonia, BacterialRetrospective StudiesStenotrophomonas maltophiliaTreatment OutcomeAnti-Infective AgentsAntimicrobial therapyCombination therapyHospital-acquired pneumoniaIntensive careStenotrophomonas maltophilia

Identifiers

PMID31752976
PMCPMC6873544
OpenAlexW2989739100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.